Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes (Q45093278)

9 December 2017

Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes (English)

1 reference

9 December 2017

Guofang Hou

1

1 reference

9 December 2017

Sheng Zhang

2

1 reference

9 December 2017

Xiaobei Zhang

3

1 reference

9 December 2017

Pei Wang

4

1 reference

9 December 2017

Xiaomeng Hao

5

1 reference

9 December 2017

Jin Zhang

6

1 reference

9 December 2017

language of work or name

English

0 references

publication date

6 January 2013

1 reference

Breast Cancer Research and Treatment

9 December 2017

1 reference

9 December 2017

137

1 reference

9 December 2017

807-816

1 reference

9 December 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-012-2404-y

9 December 2017

0 references

cites work

National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Metformin and breast cancer risk: a meta-analysis and critical literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Association between body-mass index and risk of death in more than 1 million Asians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Diabetes, metformin, and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

The location of pKi67 in the outer dense fibrillary compartment of the nucleolus points to a role in ribosome biogenesis during the cell division cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

The impact of transgenic IGF-IR overexpression on mammary development and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

Linking diabetes and cancer: a consensus on complexity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2404-Y

10.1007/S10549-012-2404-Y

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

9 December 2017

0 references

1 reference